PharmaBoardroom

BIO 2019: Hong Kong Biotech IPOs Soaring in Line with China…

With Hong Kong now established as the world’s second largest funding hub for biotech, at this week’s BIO 2019 conference in Philadelphia, the…

Esteve: Out with the Old; In with the New

Esteve has long been a family-run business, though in early 2018 the Spanish champion decided to make a daring, though calculated, move and positioned…

Servier’s Olivier Laureau: Change Instigator

Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world pharmaceuticals stage. Privately owned, smaller…

China: Driving Big Pharma’s Sales Growth for the Long Term?

China is a hot topic in Big Pharma investor updates these days. The world’s second-largest pharmaceutical market boasts sales growth that…

Hong Kong Now the World’s Second Largest Funding Hub for…

Hong Kong is now the world's second largest funding hub for biotech according to Hong Kong Chief Executive Carrie Lam. During her speech at the 2nd…

Swiss Mid-Caps and Minnows: At the Vanguard of Creativity

In view of the manifold hurdles encountered when attempting to raise capital, Switzerland’s medium capitalized entities and SMEs have grown adept at…

Spanish Mid-Caps: Going Global

Despite the Spanish economy and pharmaceutical market’s steady growth, many local players are becoming cognizant of the limitations and risks of…

Pierre Fabre: Medicalization, Convergence & the Rise of…

Iconic French skincare specialist, Pierre Fabre has been enjoying a hot streak of late, with its dermo-cosmetics business registering hefty sales…

Forging a New Path to Commercialization for Cell and Gene…

Greg Reh comments on the panel discussion from the Financial Times US Pharma and Biotech Summit about the changes needed to face coming innovations in…

The “CDP” Cure for Common “Rx” Marketing

Meghann Chilcott offers an introductory look at the potential of customer data platforms (CDPs) to transform the way pharmacy marketers reach out to…

Value Based Care: In Need of More Patient and Physician Voices

Carla Smith outlines the role that a value-based care (VBC) approach can have on both reducing healthcare costs and improving overall care delivery to…

Alzheimer’s Disease R&D Expenditure Snapshot 2019

Alzheimer's drugs represent a high-risk, high-reward proposition for global pharma. As David H. Crean recently wrote for PharmaBoardroom, "Except for…

Tagged with A